These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32030484)

  • 1. Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program.
    Mannan R; Wang X; Bawa PS; Spratt DE; Wilson A; Jentzen J; Chinnaiyan AM; Reichert ZR; Mehra R
    Med Oncol; 2020 Feb; 37(3):16. PubMed ID: 32030484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes.
    Bilé-Silva A; Lopez-Beltran A; Rasteiro H; Vau N; Blanca A; Gomez E; Gaspar F; Cheng L
    Virchows Arch; 2023 Mar; 482(3):493-505. PubMed ID: 36600115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleomorphic giant cell carcinoma of prostate: Rare tumor with unique clinicopathological, immunohistochemical, and molecular features.
    El-Zaatari ZM; Thomas JS; Divatia MK; Shen SS; Ayala AG; Monroig-Bosque P; Shehabeldin A; Ro JY
    Ann Diagn Pathol; 2021 Jun; 52():151719. PubMed ID: 33640702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
    Bowers RR; Andrade MF; Jones CM; White-Gilbertson S; Voelkel-Johnson C; Delaney JR
    BMC Cancer; 2022 Apr; 22(1):410. PubMed ID: 35421971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
    Mateo J; Porta N; Bianchini D; McGovern U; Elliott T; Jones R; Syndikus I; Ralph C; Jain S; Varughese M; Parikh O; Crabb S; Robinson A; McLaren D; Birtle A; Tanguay J; Miranda S; Figueiredo I; Seed G; Bertan C; Flohr P; Ebbs B; Rescigno P; Fowler G; Ferreira A; Riisnaes R; Pereira R; Curcean A; Chandler R; Clarke M; Gurel B; Crespo M; Nava Rodrigues D; Sandhu S; Espinasse A; Chatfield P; Tunariu N; Yuan W; Hall E; Carreira S; de Bono JS
    Lancet Oncol; 2020 Jan; 21(1):162-174. PubMed ID: 31806540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidization.
    White-Gilbertson S; Lu P; Saatci O; Sahin O; Delaney JR; Ogretmen B; Voelkel-Johnson C
    J Biol Chem; 2024 Apr; 300(4):107136. PubMed ID: 38447798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleomorphic giant cell carcinoma of the prostate: A case report and mini‑review of the literature.
    Fakhralddin SS; Ali RM; Abdullah AM; Faraj FM; Hussein DM; Mohammed SH; Abdalla BA; Kakamad FH; Rahim HM
    Med Int (Lond); 2023; 3(6):60. PubMed ID: 38222251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
    Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
    Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
    Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyploid Giant Cancer Cells Are Frequently Found in the Urine of Prostate Cancer Patients.
    Garrido Castillo LN; Anract J; Delongchamps NB; Huillard O; BenMohamed F; Decina A; Lebret T; Dachez R; Paterlini-Bréchot P
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.